BAYER AG NA O.N.BB

BAYER AG NA O.N.

22.660EURD
+0.050+0.22%
At close at Feb 28, 20:59 GMT
EUR
No trades
See on Supercharts

BAYN fundamentals

Key facts

Market capitalization‪22.31 B‬EUR
Basic EPS (TTM)−0.90EUR
Founded1952
Employees (FY)‪99.72 K‬
CEOWilliam N. Anderson
Websitebayer.com
About

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Ownership
‪‪982.42 M‬‬
Free Float shares
‪‪982.40 M‬‬ (100%)
Closely held shares
‪‪19.65 K‬‬ (0%)
Free Float shares
‪‪982.40 M‬‬ (100%)
Closely held shares
‪‪19.65 K‬‬ (0%)
Capital structure
Market cap
‪‪22.31 B‬‬
Debt
‪‪41.16 B‬‬
Minority interest
‪‪135.00 M‬‬
Cash & equivalents
‪‪4.62 B‬‬
Enterprise value
‪‪58.99 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪22.31 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.48x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.48x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪0.25‬
‪0.50‬
‪0.75‬
‪1.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−45%‬
‪−30%‬
‪−15%‬
‪0%‬
‪15%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−5.00 B‬‬
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−5.00 B‬‬
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−4.50 B‬‬
‪0.00‬
‪‪4.50 B‬‬
‪‪9.00 B‬‬
‪‪13.50 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Crop Science
Pharmaceuticals
Consumer Health
All Other
Enabling Functions and Consolidation
By country
Period: 2023
United States
Europe/Middle East/Africa
Brazil
Asia/Pacific
Latin America
China
Germany
North America
Switzerland

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Actual
Estimate
Earnings
Next:Mar 5, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
−12.28%
Payout ratio (TTM)
Dividend yield TTM
0.48%
Last payment
0.11
Last ex-date
Apr 29, 2024
Dividend history
‪0.3%‬
‪1.5%‬
‪2.7%‬
‪3.9%‬
‪5.1%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
‪2.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−16.00 B‬‬
‪0.00‬
‪‪16.00 B‬‬
‪‪32.00 B‬‬
‪‪48.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Assets
Liabilities